Experts discuss Influenza vaccine challenges and opportunities

November 30, 2017, NIH/National Institute of Allergy and Infectious Diseases
A person receives the seasonal influenza vaccine (flu shot). Credit: NIAID

In a New England Journal of Medicine perspective, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza in Melbourne discuss how the process of preparing seasonal influenza vaccines in eggs may contribute to their limited effectiveness. The authors offer research strategies that might yield more protective vaccine candidates.

Flu vaccines are updated annually to keep up with continual changes in circulating viruses. It is well-established that influenza vaccines are less effective in "mismatched" seasons when the main circulating strains change after the months-long vaccine production process has already begun. However, even in previous years when the vaccine has been well-matched to circulating , effectiveness has been low (40 to 60 percent).

Multiple factors impact the effectiveness of influenza vaccines, such as an individual's history of exposure to prior influenza viruses and vaccinations, age, genetics, and coexisting health problems. The authors note that manufacturing strategies may also play a significant role in reduced vaccine effectiveness. Currently, most influenza vaccines in the United States are produced using chicken eggs, while a few are made in cell culture or by using recombinant DNA technologies. Recently published research suggests that mutations occurring in egg-prepared vaccines may have contributed to decreased vaccine effectiveness during the 2016-2017 influenza season in the United States and the 2017 flu season in Australia. The findings underscore the need for targeted research to further evaluate manufacturing strategies and vaccine antigens and platforms, according to the authors.

Despite the limitations of the seasonal influenza vaccine, people should still get their annual flu shot, say the authors. "It is better to get vaccinated than not to get vaccinated," they write. Influenza vaccines saved 40,000 lives in the United States between 2005 and 2014, and research shows that the vaccines can reduce the risk of severe illness and death even if they fail to prevent . The authors also discuss the importance of developing a "universal" influenza , which would eliminate the need for annual shots and protect against multiple influenza subtypes—pandemic and seasonal. However, significant resources and scientific advances will be required to achieve this key goal, according to the authors.

Explore further: Live attenuated flu vaccine not effective for children in 2015-16

More information: Catharine I. Paules et al, Chasing Seasonal Influenza—The Need for a Universal Influenza Vaccine, New England Journal of Medicine (2017). DOI: 10.1056/NEJMp1714916

Related Stories

Live attenuated flu vaccine not effective for children in 2015-16

August 10, 2017
(HealthDay)—During the 2015 to 2016 season, influenza vaccines reduced the risk of influenza illness, but the live attenuated vaccine was ineffective among children 2 to 17 years of age, according to a study published in ...

Annual influenza vaccination does not prevent natural immunity

November 14, 2017
Earlier studies have suggested that having repeated annual influenza vaccination can prevent natural immunity to the virus, and potentially increase the susceptibility to influenza illness in the event of a pandemic, or when ...

Flu vaccine prevents hospitalization in children

November 17, 2017
Children vaccinated against influenza are significantly less likely to experience serious complications from the virus that could land them in hospital, new research from Public Health Ontario (PHO) and the Institute for ...

Team develops new broadly protective vaccines for H3N2 influenza

November 2, 2017
A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur, the largest influenza vaccine manufacturer in the world, has resulted in the identification of a vaccine ...

Influenza vaccines in pediatric ERs likely cost-effective

November 7, 2017
(HealthDay)—Influenza vaccination in the pediatric emergency department (PED) setting appears to be a cost-effective strategy, according to a study published online Nov. 6 in JAMA Pediatrics.

Experts say flu season could be severe this year

September 22, 2017
If last year's active flu season and this year's severe season in the Southern Hemisphere is any indication of what flu season will look like across the country beginning this fall, then it's important to get vaccinated soon ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.